Investor Presentation First Nine Months of 2022
44
Novo NordiskⓇ
Investor presentation First nine months of 2022
OzempicⓇ launch has helped drive the changing treatment.
paradigm in the US
15% intensify with non-generic treatment
within 18 months of starting metformin
OzempicⓇ launch increases the use of GLP-1
as intensification after metformin
More than 60% of patients choose Novo
Nordisk GLP-1 products
39%
15%
25%
17%
11%
35%
15%2
People starting
on metformin¹
Treatment change
within 18 months
Before OzempicⓇ
launch
After OzempicⓇ
launch
GLP-1 choice
Non-generic
Generic
Metformin
Insulin
GLP-1
SGLT-2i
DPP-4i
■■Ozempic
Ⓡ
Ⓡ
Rybelsus
VictozaⓇ
Other
OAD: oral anti-diabetes medication;
Note: All numbers are from the North America Operations. The analysis is made by comparing patients starting metformin in Q1 2017 with patients starting metformin in Q4 2019 and has 300+ unique regimens grouped based on subclass hierarchy
(GLP-1 reflects GLP-1 only, as well as regimens including any combination of subclasses), regimens hierarchy: insulin, GLP-1, SGLT-2i, DPP-4i, generic. Considering patients that started on Metformin (844K patients)
Source: IQVIA, MAT Dec'21View entire presentation